3 New Strong Buy Ratings from Top-Rated Analysts: 05/22/2026
While everyone’s eyes are on NVDA, these stocks are quietly gaining momentum:
- Nature's Sunshine Products (NATR) — Wellness leader eyes 50% upside with #1 industry rank.
- Insulet Corporation (PODD) — Diabetes tech giant targets up to 187% upside surge.
- Atlassian Corp (TEAM) — AI-powered software play with 50% upside potential ahead.
P.S. Get more alerts like this daily … Try WallStreetZen Premium.
A note from our sponsors...
Windfall Profit Potential For These 5 Summer Stocks From peak travel demand to the World Cup to home improvement season, summer drives the business behind each of these 5 companies. This free report covers the catalysts, fundamentals and analyst price targets. Click here to access your free copy.1. Nature's Sunshine Products (NASDAQ: NATR)
This global wellness powerhouse — manufacturing and selling nutritional and personal care products across Asia, Europe, North America, and Latin America — is firing on all cylinders. Strong Q1 2026 results just drove investor interest sky-high, and with NATR now ranking #1 in the Food industry, this defensive consumer play has Wall Street paying close attention.
Zen Rating: Strong Buy (A) — see full analysis
Recent Price: $21.93 — get current quote
Max 1-year forecast: $33.00
Why we're watching:
- Analyst support: 2 analysts cover NATR with a unanimous Strong Buy consensus, with price targets that suggest over 50% potential upside. See the ratings
- Canaccord Genuity researcher Susan Anderson (a top 17% rated analyst) recently maintained her Strong Buy rating following the company's Q4 and FY 2025 earnings report. Anderson noted the results showed strength across all regions and strong growth in the company's digital business.
- DA Davidson recently maintained their $33 price target, representing +50.48% upside potential from current levels, highlighting confidence in the company's growth trajectory.
- Despite good earnings and solid backing from analysts, the stock is down for no particular reason — which, as our Zen Investor Editor-in-Chief Steve Reitmeister observed, could make it a fantastic buy the dip opportunity. Read his detailed commentary here.
- Industry ranking context: NATR is currently the #1 highest-rated stock in the Food industry.
- Zen Rating highlights: As a Strong Buy-rated stock, NATR is already in a class of stocks that have historically delivered over 32% annual returns. But within that top tier, it actually ranks in the top 1% of stocks we track based on fundamentals — no small feat.
- Component Grades: NATR shows exceptional strength with A grades in both Value and AI, plus B grades in Sentiment and Financials, indicating strong analyst conviction and attractive valuation metrics. (See all 7 Zen Component Grades here)
2. Atlassian Corp (NASDAQ: TEAM)
The global software giant behind Jira and other cloud-based collaboration platforms used by businesses worldwide is riding an AI-powered breakout. A blowout Q3 2026 earnings beat sent total revenue soaring 32% year-over-year to $1.8B, and with analysts piling in on TEAM's AI-powered platform strategy, this name is becoming Wall Street's go-to enterprise software pick.
Zen Rating: Strong Buy (A) — see full analysis
Recent Price: $86.23 — get current quote
Max 1-year forecast: $190.00
Why we're watching:
- Analyst support: 17 analysts cover TEAM with 11 Strong Buy ratings, 4 Buy ratings, and 2 Hold ratings. See the ratings
- Barclays researcher Raimo Lenschow (a top 3% rated analyst) recently maintained his Strong Buy rating with a $112 price target. Piper Sandler's Rob Owens (a top 4% rated analyst) maintained his Strong Buy with the highest price target at $175, representing +102.95% upside potential.
- Cantor Fitzgerald analyst Thomas Blakey (a top 13% rated analyst) highlighted the company's strong Q3 performance, noting accelerating cloud growth, strong momentum in Service and Teamwork Collections, and robust RPO expansion as key drivers of the quarter's beat.
- Industry ranking context: TEAM is currently the #8 highest-rated stock in the App industry, which has an Industry Rating of B.
- Zen Rating highlights: Strong Buy (A) stocks average +32.52%/yr, putting TEAM in a class of superachiever stocks.
- Component Grades: The company shows impressive strength in Growth and Financials (both A grades), with return on equity of 222.73% significantly outpacing industry averages and revenue growth forecast at 12.44%. (See all 7 Zen Component Grades here)
A note from our sponsors...
Windfall Profit Potential For These 5 Summer Stocks From peak travel demand to the World Cup to home improvement season, summer drives the business behind each of these 5 companies. This free report covers the catalysts, fundamentals and analyst price targets. Click here to access your free copy.3. Insulet Corporation (NASDAQ: PODD)
The diabetes care leader behind the revolutionary Omnipod System — a self-adhesive, tubeless insulin delivery device that's reshaping diabetes management — is firing on all cylinders. PODD just earned a Strong Buy consensus from 17 analysts following recent earnings, with top-rated analysts setting price targets as high as $450 — a setup that's hard for growth investors to ignore.
Zen Rating: Strong Buy (A) — see full analysis
Recent Price: $156.59 — get current quote
Max 1-year forecast: $450.00
Why we're watching:
- Strong upside potential: Looking for a stock that could nearly 2x? Right now, 13 of the analysts we track issue either Buy or Strong Buy ratings for PODD, with a max price target that suggests over 180% potential upside in the coming year. See the ratings
- Worth noting: Those targets aren’t stale. Multiple analysts raised or maintained Strong Buy ratings in early May 2026, with Canaccord Genuity’s Kyle Rose (a top 16% rated analyst) setting the highest price target at $450, which as noted above suggests significant upside potential.
- The company's financial forecasts show strong momentum with earnings expected to grow 33.54% and revenue growth of 17.84%, both significantly outpacing industry averages.
- Industry ranking context: PODD is currently the #4 highest-rated stock in the Medical Device industry, which has an Industry Rating of C.
- Zen Rating highlights: PODD earns an overall Zen Rating of A (Strong Buy) following a 115-factor fundamental review. It’s not easy to earn this rating — only the top 5% of stocks we track make the cut.
- Component Grades: Each Zen Rating is composed of 7 Component Grades. The company's Financials component ranks exceptionally high, reflecting a strong balance sheet with 12% profit margins and robust operating cash flow of $619.3M. (See all 7 Zen Component Grades here)
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.